SCHEMBL31258254

SCHEMBL31258254

N[C@@H](CCCCNC(=O)CCc1cccnc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
PTAFR P25105 5/20 0.54
ALDH1A1 P00352 2/20 0.54
EPHX2 P34913 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
FES P07332 1/20 0.47
RET P07949 1/20 0.47
MARK3 P27448 1/20 0.47
TYK2 P29597 1/20 0.47
FLT4 P35916 1/20 0.47
SYK P43405 1/20 0.47
CLK2 P49760 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
TBXAS1 P24557 3/20 0.47
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8235888 1.00 CYP3A4 (0.55) CYP3A4CYP1A2CYP2C9CYP2C19PTAFR
SCHEMBL31268378 0.88 EPHX2 (0.62) CYP3A4CYP1A2CYP2C9PTAFREPHX2
SCHEMBL7742589 0.88 EPHX2 (0.62) CYP3A4CYP1A2CYP2C9PTAFREPHX2
SCHEMBL6014960 0.86 HPGD (0.63) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL31268361 0.85 HPGD (0.49) ALDH1A1EPHX2HPGDGAA
SCHEMBL24636718 0.85 FOLH1 (0.55) CYP3A4CYP1A2CYP2C9CYP2C19PTAFR
SCHEMBL2234915 0.84 EPHX2 (0.64) CYP3A4CYP1A2CYP2C9PTAFREPHX2
SCHEMBL2234907 0.84 EPHX2 (0.64) CYP3A4CYP1A2CYP2C9PTAFREPHX2
SCHEMBL31371834 0.82 TBXAS1 (0.52) CYP3A4CYP1A2CYP2C9CYP2C19TBXAS1
SCHEMBL24636604 0.82 TBXAS1 (0.70) CYP3A4CYP1A2CYP2C9CYP2C19PTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098717-A1 POLYPEPTIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 中山莱博瑞辰生物医药有限公司 2026-05-15 WO claimed
WO-2026098717-A1 POLYPEPTIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 中山莱博瑞辰生物医药有限公司 2026-05-15 WO disclosed
US-12157778-B2 Peptides for activation of cell signaling in osteoprogenitor cells THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157778-B2 Peptides for activation of cell signaling in osteoprogenitor cells ITGB4, ITGA4, ITGB1 CYP3A4 4307/4885CYP1A2 4843/4885CYP2C9 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.